Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for lactate reduction in asphyxiated newborns receiving hypothermia
IRCT20260108068589N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of pentoxifylline in hypoxic-ischemic encephalopathy (HIE) and asphyxia neonatorum (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Serum lactate level at 72 hours. Started Feb 2026; status: completed.
02
Drugs
pentoxifylline
03
Conditions
hypoxic-ischemic encephalopathy (HIE)asphyxia neonatorum
Beyond the preview
Go deeper on IRCT20260108068589N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260108068589N1.